Drug Profile
House dust mite allergy immunotherapy - ALK-Abello
Alternative Names: ACARIZAX; ALK HDM; ALK Mite Tablet; HDM AIT; HDM SLIT drops - ALK-Abello; HDM SLIT extract - ALK-Abello; HDM SLIT tablet- ALK-Abello; House dust mite extract - ALK-Abello; House dust mite SLIT drops - ALK-Abello; House dust mite SLIT One Dermatophagoides mixture - ALK-Abello; House dust mite SLIT tablet - ALK-Abello; MITICURE; Mitizax; MK-8237; Odactra; SCH-900237; SLITONEULTRA-HDM; SQ®HDM SLIT-tablet - ALK-Abello; TO-203Latest Information Update: 02 Feb 2024
Price :
$50
*
At a glance
- Originator ALK-Abello
- Developer Abbott Laboratories; ALK-Abello; Merck & Co; Seqirus; Torii Pharmaceutical
- Class Allergens; Allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Allergic asthma; Allergic rhinitis; Allergic rhinoconjunctivitis
- Phase III Atopic dermatitis; Rhinoconjunctivitis
Most Recent Events
- 25 Jan 2024 Preregistration for Allergic rhinitis (In children) in European Union (Sublingual)
- 25 Jan 2024 ALK-Abelló announces intention to submit BLA to US FDA for Allergic rhinitis (In children) (Sublingual, Tablet) in first half of 2024
- 25 Jan 2024 ALK-Abello completes the phase III MATIC trial in Allergic rhinitis (In children) in USA, Bulgaria, Canada, France, Germany, Lithuania, Poland, Russia, Slovakia, Spain, Ukraine (Sublingual, Tablet) before January 2024 (NCT04145219)